Brokerages predict that Collegium Pharmaceutical Inc (NASDAQ:COLL) will post $76.18 million in sales for the current quarter, according to Zacks. Six analysts have provided estimates for Collegium Pharmaceutical’s earnings, with the lowest sales estimate coming in at $74.80 million and the highest estimate coming in at $78.35 million. Collegium Pharmaceutical posted sales of $73.06 million in the same quarter last year, which suggests a positive year-over-year growth rate of 4.3%. The firm is expected to report its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Collegium Pharmaceutical will report full year sales of $308.31 million for the current financial year, with estimates ranging from $304.16 million to $312.18 million. For the next year, analysts anticipate that the company will report sales of $344.06 million, with estimates ranging from $332.00 million to $356.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. The business had revenue of $74.52 million during the quarter, compared to analyst estimates of $70.10 million. Collegium Pharmaceutical had a negative return on equity of 30.87% and a negative net margin of 10.36%.
Shares of NASDAQ:COLL opened at $13.15 on Friday. Collegium Pharmaceutical has a 52-week low of $10.55 and a 52-week high of $25.13. The company has a market capitalization of $439.04 million, a PE ratio of -11.05 and a beta of 0.47. The business has a 50 day moving average price of $12.20. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.19 and a current ratio of 1.24.
In other Collegium Pharmaceutical news, CEO Joseph Ciaffoni sold 7,436 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $11.59, for a total transaction of $86,183.24. Following the completion of the sale, the chief executive officer now owns 190,755 shares in the company, valued at $2,210,850.45. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $11.37, for a total value of $284,250.00. Following the sale, the director now owns 159,090 shares of the company’s stock, valued at approximately $1,808,853.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 88,287 shares of company stock valued at $1,136,087. 8.08% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of COLL. Macquarie Group Ltd. raised its stake in Collegium Pharmaceutical by 8.7% in the 4th quarter. Macquarie Group Ltd. now owns 2,759,007 shares of the specialty pharmaceutical company’s stock worth $47,372,000 after acquiring an additional 221,779 shares during the last quarter. BlackRock Inc. raised its stake in Collegium Pharmaceutical by 8.7% in the 4th quarter. BlackRock Inc. now owns 2,619,718 shares of the specialty pharmaceutical company’s stock worth $44,980,000 after acquiring an additional 210,145 shares during the last quarter. Millennium Management LLC raised its stake in Collegium Pharmaceutical by 863.4% in the 4th quarter. Millennium Management LLC now owns 1,305,001 shares of the specialty pharmaceutical company’s stock worth $22,407,000 after acquiring an additional 1,169,537 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in Collegium Pharmaceutical by 27.8% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,191,141 shares of the specialty pharmaceutical company’s stock worth $18,034,000 after acquiring an additional 259,015 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Collegium Pharmaceutical by 2.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 663,498 shares of the specialty pharmaceutical company’s stock worth $11,392,000 after acquiring an additional 13,874 shares during the last quarter. Hedge funds and other institutional investors own 94.15% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Read More: Understanding the two types of arbitrage
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.